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The heat-shock response co-inducer arimoclomol
protects against retinal degeneration in rhodopsin
retinitis pigmentosa
DA Parfitt1,4, M Aguila1,4, CH McCulley1,4, D Bevilacqua1, HF Mendes1, D Athanasiou1, SS Novoselov1, N Kanuga1, PM Munro1,
PJ Coffey1, B Kalmar2, L Greensmith2,3 and ME Cheetham*,1
Retinitis pigmentosa (RP) is a group of inherited diseases that cause blindness due to the progressive death of rod and cone
photoreceptors in the retina. There are currently no effective treatments for RP. Inherited mutations in rhodopsin, the light-
sensing protein of rod photoreceptor cells, are the most common cause of autosomal-dominant RP. The majority of mutations in
rhodopsin, including the common P23H substitution, lead to protein misfolding, which is a feature in many neurodegenerative
disorders. Previous studies have shown that upregulating molecular chaperone expression can delay disease progression in
models of neurodegeneration. Here, we have explored the potential of the heat-shock protein co-inducer arimoclomol to
ameliorate rhodopsin RP. In a cell model of P23H rod opsin RP, arimoclomol reduced P23H rod opsin aggregation and improved
viability of mutant rhodopsin-expressing cells. In P23H rhodopsin transgenic rat models, pharmacological potentiation of the
stress response with arimoclomol improved electroretinogram responses and prolonged photoreceptor survival, as assessed by
measuring outer nuclear layer thickness in the retina. Furthermore, treated animal retinae showed improved photoreceptor outer
segment structure and reduced rhodopsin aggregation compared with vehicle-treated controls. The heat-shock response (HSR)
was activated in P23H retinae, and this was enhanced with arimoclomol treatment. Furthermore, the unfolded protein response
(UPR), which is induced in P23H transgenic rats, was also enhanced in the retinae of arimoclomol-treated animals, suggesting
that arimoclomol can potentiate the UPR as well as the HSR. These data suggest that pharmacological enhancement of cellular
stress responses may be a potential treatment for rhodopsin RP and that arimoclomol could benefit diseases where ER stress is
a factor.
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Retinitis pigmentosa (RP) is a group of heterogeneous
disorders characterised by progressive rod photoreceptor
loss followed by cone cell death in the retina.1 There are
currently no effective therapies for RP. Rhodopsin was the
first RP gene identified,2 and mutations in rhodopsin are the
most common cause of autosomal-dominant RP (RetNet).
Rhodopsin is formed of rod opsin protein and the chromo-
phore 11-cis-retinal. The most common point mutation in
North America is the proline to histidine change at residue 23,
hereafter referred to as P23H. Rod opsinmutations have been
classified according to their cellular and biochemical
characteristics.3 Class II rod opsin mutations are the most
common and include P23H, which is misfolded and retained in
the endoplasmic reticulum (ER), occasionally forming visible
intracellular inclusions of aggregated protein.4,5 There is also
evidence that the P23H mutation has a dominant-negative
effect on wild-type rhodopsin4,6,7 and can affect outer
segment (OS) disc formation and stability.8,9
Within the cell, a network of dedicated protein-folding
mechanisms function to assist proteins attain their correct
conformation and perform quality control on misfolded or
damaged proteins, thereby establishing protein homeosta-
sis or proteostasis.10 These mechanisms include the heat-
shock response (HSR) and unfolded protein response
(UPR). In the HSR, following cell stress molecular chaper-
ones, such as Hsp70 and Hsp90, dissociate from their
transcription factor heat-shock factor 1 (HSF1) and bind
misfolded proteins. HSF1 is posttranslationally modified and
trimerises before trafficking to the nucleus to induce
molecular chaperone expression.11,12 There are three
distinct branches of the UPR that respond to ER stress:
IRE1a, PERK, and ATF6a.13,14 BiP (HSPA5), the resident
Hsp70 orthologue in the ER, regulates all three branches.
IRE1a (inositol requiring enzyme-1) activation results in the
correct splicing of XBP1, which can act as a transcription
factor to upregulate ER chaperones and ER-associated
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degradation (ERAD) components. ATF6 (activating transcription
factor 6) traffics to the Golgi, where it is cleaved, and the
N-terminal fragment enters the nucleus, where it upregulates
molecular chaperones and quality-control components.
PERK (double-stranded RNA-activated protein kinase
(PKR)-like ER kinase) autophosphorylation results in eIF2a
phosphorylation, which leads to the inhibition of protein
synthesis. However, selective transcription of certain genes
still occurs; the transcription factor ATF4 is one of these,
which leads to upregulation of the pro-apoptotic protein CHOP
and phosphatase GADD34. In cells with high protein turnover,
these networks are particularly important to preserve
proteostasis. Rod photoreceptors produce large amounts of
rhodopsin, and mutant rhodopsin can induce the UPR,15
highlighting the role of these networks in adapting to protein
misfolding stress in photoreceptors.16
Much recent work has focused on the role of these networks
to alleviate protein misfolding diseases, especially the
targeted upregulation of these mechanisms to reduce protein
aggregation and restore proteostasis. Hsp90 inhibition is a
potentmethod for inducing theHSR. Hsp90 inhibitors, such as
geldanamycin and its analogues, bind the ATP-binding pocket
of Hsp90 and block its ATPase cycle, thus releasing HSF1,
which can activate heat-shock protein expression.17,18 Inhibi-
tion of Hsp90 can reduce P23H rhodopsin inclusion formation,
insolubility and reduce P23H rod opsin-associated cell
death.19 Recently, Hsp90 inhibition was shown not only to
reduce P23H rhodopsin-mediated photoreceptor cell death
in vivo but can also potentially affect normal visual function,
suggesting that other mechanisms to induce the stress
response might be desirable.20
The hydroxylamine derivative bimoclomol is a co-inducer of
the HSR, which can potentiate a pre-existing HSR and
enhance the expression of inducible molecular chaperones
(e.g., Hsp70) when combined with a cellular stress event such
as heat shock, ischemia, or pancreatitis.21,22 Interestingly,
bimoclomol treatment also resulted in a functional improve-
ment in a rat model of diabetic retinopathy, with increased
b-wave electroretinogram (ERG) amplitude compared with
vehicle-treated rats.23 Arimoclomol (also known as BRX-345)
is an analogue of bimoclomol and a citrate formulation of a
previously used maleate formulation analogue (BRX-220),
which has a longer half-life and better uptake than bimoclo-
mol. In a rat sciatic nerve crush model, treatment with BRX-
220 increased motor neuron survival.24 Arimoclomol also
improved motor neuron survival in both the SODG93A mouse
model of amyotrophic lateral sclerosis (ALS)25,26 and amouse
model of spinal bulbar muscular atrophy, a CAG-repeat
disorder.27 Bimoclomol and its analogues BRX-220 and
arimoclomol have been shown to prolong and increase the
activation of HSF1,25,28 which leads to increased upregulation
of Hsp70 and Hsp90, in vitro21 and in vivo.25,26
In the present study, we investigated the effect of
arimoclomol treatment on in vitro and in vivo models
of P23H rhodopsin RP. Arimoclomol treatment reduced
inclusion incidence and cell death in a cell model.
Furthermore, arimoclomol treatment in P23H rats preserved
retinal function and photoreceptor survival. We show that
these effects are related to the potentiation of both the HSR
and UPR.
Results
Arimoclomol reduces P23H aggregation and improves
cell viability in SK-N-SH cells. Pharmacological chaper-
ones, kosmotropes and molecular chaperone inducers can
affect rod opsin folding and aggregation in cell models.19,20
Arimoclomol is an HSR potentiating compound; therefore, we
initially investigated the effect of arimoclomol on HSR
activation in SK-N-SH cells expressing wild-type or P23H
rod opsin tagged with GFP (WT-GFP and P23H-GFP,
respectively). A significant increase in Hsp70 level was
observed in P23H-GFP-expressing cells treated with arimo-
clomol compared with vehicle-treated P23H-GFP cells
(Figures 1a and b). Furthermore, there appeared to be a
small decrease in the amount of higher molecular weight
species of P23H-GFP rod opsin in treated cells compared
with untreated cells (Figure 1c), potentially corresponding to
higher-order complexes of rod opsin. As previously
reported,4 WT-GFP trafficked to the plasma membrane
(Figure 1d), whereas P23H-GFP was retained in the ER,
and occasionally formed intracellular inclusions (Figure 1e).
Arimoclomol treatment led to a dose-dependent decrease in
the incidence of cells with inclusions, from 27% in vehicle
treated P23H-GFP expressing cells to o5% in cells treated
with 1 or 5mM arimoclomol (Figures 1f and g). Similarly,
P23H-GFP cells treated with 1mM arimoclomol had reduced
amounts of sedimentable, insoluble rod opsin (Figure 1h).
Arimoclomol did not affect WT-GFP expression. Further-
more, P23H-GFP cells treated with arimoclomol had reduced
cell death compared with vehicle-treated P23H-GFP cells,
as measured by a lactate dehydrogenase (LDH) assay
(Figure 1i).
Arimoclomol treatment improves visual function in P23H
rats. Given the positive effect of arimoclomol on mutant rod
opsin observed in this cell model, we investigated arimoclo-
mol treatment in an in vivomodel, using two lines of the P23H
rat.29 Line 1 P23H (P23H-1) rats undergo rapid photorecep-
tor degeneration, while line 3 P23H (P23H-3) have a
markedly slower degeneration.30,31 All animals were treated
daily with 10mg/kg arimoclomol by intraperitoneal injection, a
dose that has been shown to be effective in SOD1G93A
mice.25 P23H-1 rats were treated from P21 (3 weeks of age)
to either P35 (5 weeks of age) or P49 (7 weeks of age), while
P23H-3 rats were treated from P21 to either P49 or P63
(9 weeks of age). All animals were tested for visual function
improvements by scotopic ERG measurements (Figure 2).
Both a- and b-wave response amplitudes were improved in
P23H-1 and P23H-3 rats following arimoclomol treatment
(Figures 2b–e), compared with vehicle-treated animals.
Arimoclomol treatment protects against P23H-mediated
photoreceptor degeneration. After ERG examinations,
eyes were excised and examined for changes in retinal
architecture by histological analysis. We measured outer
nuclear layer (ONL) thickness as a measure of photoreceptor
survival. In P23H-1 rats, ONL thickness was preserved
across the entire retina in treated animals compared with
vehicle-treated animals (Figure 2f), and mean ONL thickness
was significantly maintained at all time points in both strains
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(Figures 2g and h). Rhodopsin expression was investigated
in retinae of both wild-type Sprague Dawley (SD) rats and
treated and vehicle-treated P23H-1 animals at P35. As
expected, SD rat retinae showed rhodopsin expression in the
OS (Figure 3a); however, in P23H retinae there was a
marked reduction of OS rhodopsin staining and increased
rhodopsin expression in the ONL, which suggests that P23H
rhodopsin is not trafficked correctly and might affect the
traffic of wild-type rhodopsin (Figure 3a, arrows). In
arimoclomol-treated rats, there appeared to be an increase
in OS length as assessed by rhodopsin staining and a
decrease in ONL rhodopsin staining (Figure 3a). Further
examination of arimoclomol-treated and vehicle-treated eyes
in semi-thin resin-embedded sections revealed a significant
increase in OS length in arimoclomol-treated animals, from
approximately 5 mm to 10mm (Figures 3b and c). Transmis-
sion electron microscopy (TEM) was used to analyse the
rod structure in more detail. P23H-1 rats had a disorganised
rod OS structure with loosely packed, misorientated discs
and more vesicular structures, whereas in arimoclomol-treated
animals the general disorganisation was reduced (Figure 3d).
Interestingly, the amount of total and soluble rhodopsin was
found to be similar in both vehicle- and arimoclomol-treated
eyes when normalised to tubulin (Figures 3e and f), but
Figure 1 Arimoclomol induces the HSR and reduces aggregation of P23H-GFP in cells. (a) Representative western blots of SK-N-SH cell lysates transfected with either
GFP alone or WT- or P23H-GFP, and treated with vehicle (water) or 1 mM arimoclomol for 24 h, for Hsp70, Hsp90, or tubulin, as indicated. (b) Quantification of expression
levels of Hsp70 in transfected SK-N-SH cells, normalised to tubulin. Relative expression to vehicle-treated cells transfected with GFP only was calculated by densitometric
analysis. Values are mean±2S.E.M. Statistical significance was determined using analysis of variance, *Po0.05. (c) Western blots for GFP for cells transfected with
WT- or P23H-GFP and treated as indicated. Molecular weight markers (in kDa) are indicated to the left of blots. Tubulin was used as a loading control. (d–f) Representative
images of WT-GFP, P23H-GFP and P23H-GFP treated with 1 mM arimoclomol localisation in cells. Arrow in panel (d) indicates the presence of WT-GFP at the plasma
membrane, whereas asterisk in panel (e) indicates intracellular inclusion formed by P23H-GFP. Scale bar 10 mm. (g) P23H-GFP-expressing cells were treated with increasing
concentrations of arimoclomol, and inclusion incidence was assessed. Values are mean±2 S.E.M. (h) WT- and P23H-GFP cells treated with 1 mM arimoclomol were
examined for the amount of insoluble sedimentable protein present using a rod opsin fractionation assay. Values are mean±2 S.E.M., and statistical significance was
determined using the Student’s t-test, **Po0.01. (i) Cells were subjected to LDH release assay to assess cell death. Values are mean±2 S.E.M., and statistical
significance was determined using the Student’s t-test, following removal of GFP background, **Po0.01
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fractionation analysis of the retina revealed that there was a
significant reduction in insoluble rhodopsin in arimoclomol-
treated animals (Figure 3g).
Arimoclomol potentiates pre-existing stress responses
in P23H-1 rats. Arimoclomol potentiated the HSR in the
presence of P23H-GFP in cells (Figure 1); therefore, we
investigated whether arimoclomol enhanced the HSR in
P23H-1 rats. P23H-1 rat retinae at P35 had slightly elevated
levels of Hsp70 and Hsp90, and an increase in posttransla-
tionally modified HSF1 with a slower mobility compared with
SD control animals, suggesting a pre-existing induction of the
HSR (Figure 4a). Treatment with arimoclomol further
increased Hsp70 and Hsp90 expression levels and increased
mobility shifted HSF1 (Figures 4a and b). As the P23H
mutation causes rod opsin misfolding and retention in the ER
and has been reported to induce the UPR,15,32 we examined
P23H rod opsin models for changes in the ER-resident
molecular chaperone BiP, which is a marker of the UPR. In
SK-N-SH cells expressing WT- or P23H-GFP, BiP levels
were slightly elevated in untreated P23H-GFP cells, although
this increase was not significant (Figures 5a and b).
Arimoclomol treatment led to a significant increase in BiP
levels in P23H-GFP cells compared with untreated cells
expressing GFP only. In P23H-1 rat retinae BiP levels were
increased at P35, compared with SD controls, and a further
increase was observed following arimoclomol treatment
(Figures 5c and d). Furthermore, this increase was confirmed
and localised by immunohistological analyses of wild-type
and P23H retinae. BiP levels were markedly increased in the
inner segment and ONL of the photoreceptors (Figure 5e).
Interestingly, the levels of BiP changed most dramatically in
the ONL of P23H-1 and arimoclomol-treated P23H-1 retinae,
whereas there were higher levels of constant expression in
the bipolar cells (in the inner nuclear layer) and retinal
ganglion cells (Supplementary Figure S1) in all animals. The
UPR has three distinct branches (IRE1a, PERK, and ATF6a),
each with different downstream effects.13 Therefore we also
examined several UPR markers from each branch (Figure 6
and Supplementary Figure S2). Western blotting analysis
showed that levels of phosphorylated eIF2a, ATF4, GADD34,
and cleaved ATF6a (ATF6-N) were all increased in P23H-1
retinae compared with SD retinae, supporting induction of the
UPR, as previously reported.15 In the arimoclomol-treated
P23H-1 retinae, these UPR markers were also significantly
increased compared with SD. In addition, the increase in
phosphorylated IRE1a reached statistical significance
(Supplementary Figure S2). Most of the UPR markers were
elevated in P23H-1 retinae treated with arimoclomol compared
with vehicle but did not reach statistical significance;
however, there was a significant increase in phosphorylated
eIF2a (Figures 6a–c and Supplementary Figure S2). XBP1
splicing was examined via a RT-PCR assay using primers
specifically targeting the spliced intron (Figure 6d). P23H-1
retinae showed increased XBP1 splicing compared with wild
type, and a further increase after arimoclomol treatment was
Figure 2 Arimoclomol improves ERG response and photoreceptor survival in P23H rats. (a) Representative scotopic ERG traces of P23H-1 rats at P35 after treatment
with vehicle (water) or 10mg/kg arimoclomol for 2 weeks. (b and c) P23H-1 and (d and e) P23H-3 rats were treated with either vehicle or arimoclomol (n¼ 5 for each condition)
and were assessed for retinal function at 5, 7, or 9 weeks, as indicated. Values represent mean scotopic ERG response for a- and b-waves. Intensity¼ 1 log10 c.d.s./m2
±2S.E.M. Statistical significance was determined using the Student’s t-test, *Po0.05, **Po0.01, ***Po0.001. (f–h) P23H-1 and P23H-3 rats were treated with either
vehicle (water) or 10mg/kg arimoclomol (n¼ 5 for each condition) and were assessed for alterations in retinal histology at 5, 7, or 9 weeks, as indicated. (f) Spider plot of ONL
thickness in P23H-1 rats at 5 weeks after vehicle or arimoclomol treatment. (g and h) The mean ONL thickness across the whole retina was analysed by averaging the
measurements used in spider plots. Values are mean±2S.E.M. Statistical significance was determined using the Student’s t-test, *Po0.05, **Po0.01, ***Po0.001
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observed (Figure 6e). These data are consistent with
arimoclomol treatment enhancing the activation of all three
branches of the UPR in the presence of P23H mutant
rod opsin.
Discussion
Arimoclomol and related hydroximic acid derivatives (HADs)
have been shown to be protective in several models of
disease. Here, we investigated the therapeutic potential of
arimoclomol for P23H rhodopsin-mediated retinal degenera-
tion. In SK-N-SH cells, arimoclomol reduced P23H aggrega-
tion but did not lead to improved trafficking of P23H rod opsin.
However, this was sufficient to reduce P23H rod opsin-
mediated cell death. This correlation between reduced rod
opsin aggregation and improved cell viability was also
observed for kosmotropes, Hsp90 inhibitors,19 and BiP
overexpression.32,33 Furthermore, the rescue of P23H
Figure 3 Arimoclomol treatment improves OS structure, rhodopsin localisation and solubility in P23H-1 rats. (a) Representative images of the ONL in either 5-week-old
wild-type, P23H-1 rats treated with vehicle (water) or 10mg/kg arimoclomol for 2 weeks. Cryosections were stained with DAPI (blue), anti-rhodopsin antibody 1D4 (green), and
cone marker peanut agglutinin (PNA; red). Scale bar 20 mm. (b) Representative images of semi-thin resin sections of 5-week-old P23H-1 retina stained with toluidine blue.
Scale bar 10mm. (c) Quantification of OS length in vehicle- or arimoclomol-treated P23H-1 rats. Values represent mean±2S.E.M., n¼ 3 per treatment. Statistical
significance was determined using the Student’s t-test, **Po0.01. (d) Representative TEM images of vehicle- and arimoclomol-treated P23H-1 retina showing the structure of
the rod OS. Scale bar 500 nm. (e–g). Representative western blots and densitometric analysis of (e) total, (f) soluble, and (g) insoluble rod opsin levels in vehicle- or
arimoclomol-treated P23H-1 rats at 5 weeks. Molecular weight markers (in kDa) are indicated to the left of blots. Tubulin was used as a loading control. Values represent
mean±2 S.E.M., n¼ 3 per treatment. Statistical significance was determined using the Student’s t-test ***Po0.001
Figure 4 Arimoclomol treatment co-induces the HSR in P23H-1 rats.
(a) Representative western blots of retinal lysates from P23H-1 rats at 5 weeks old
treated with vehicle (water) or 10mg/kg arimoclomol for 2 weeks. Antibodies against
the HSR markers Hsp70, Hsp90, and HSF1 are shown, as indicated. Actin was used
as a loading control. (b and c) Quantification of the expression levels of (b) Hsp70 and
(c) Hsp90 levels in wild-type or vehicle- or arimoclomol-treated P23H-1 rats, relative to
actin. Relative expression to wild-type rats was calculated by densitometric analysis.
Values are mean±2 S.E.M., n¼ 5 per treatment. Statistical significance was
determined by using analysis of variance, *Po0.05, **Po0.01
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misfolding by molecular chaperones or pharmacological
chaperones has revealed that the protein is intrinsically
unstable.34,35 Collectively, these data suggest that enhancing
P23H rod opsin solubility and improved protein quality control
may be more important than improving protein folding to
counteract the toxic effects of mutant rod opsin.
It has been shown that rhodopsin expression is reduced in
P23H-1 transgenic rats from at least postnatal day 30 (P30)
Figure 5 Arimoclomol treatment potentiates upregulation of BiP in P23H-1 rats. (a) Representative western blots of BiP expression in lysates from SK-N-SH cells
transfected with GFP only, WT-GFP, or P23H-GFP after 24 h of treatment with vehicle of 1 mM arimoclomol. Actin was used as a loading control. (b) Quantification of the BiP
expression levels in SK-N-SH cells in panel (a), relative to actin. Relative expression to wild-type rats was calculated by densitometric analysis. Values are mean±2 S.E.M.
Statistical significance was determined by using analysis of variance (ANOVA), *Po0.05. (c) Representative western blots of BiP expression in retinal lysates from wild-type
or vehicle- or arimoclomol-treated P23H-1 rats at P35. (d) Quantification of the BiP expression levels in wild-type or vehicle- or arimoclomol-treated P23H-1 rats, relative to
actin. Relative expression to wild-type rats was calculated by densitometric analysis. Values are mean±2 S.E.M., n¼ 5 per treatment. Statistical significance was
determined by using ANOVA, *Po0.05, ***Po0.001. (e) Representative identical intensity images of BiP immunohistochemistry in wild-type or vehicle- or arimoclomol-
treated P23H-1 rats at P35. Cryosections were stained with DAPI (blue), anti-rhodopsin antibody 1D4 (green), and anti-BiP (red). The different layers of the retina are indicated
to the right of the image: OS; IS¼ inner segment; and ONL. Scale bar 10 mm
Figure 6 Arimoclomol treatment potentiates upregulation of the UPR in P23H-1 rats. (a–c) Representative western blots of retinal lysates from wild-type or P23H-1 rats at
P35 for antibodies against the three branches of the UPR: (a) the PERK branch (phosphorylated eIF2a, ATF4 (arrow indicates specific ATF4 band) and GADD34); (b) the
ATF6 branch (cleaved or nuclear (N) ATF6 and full-length (FL) ATF6); and (c) the IRE1a branch (phosphorylated IRE1a). Actin was used as a loading control throughout.
(d) RT-PCR using primers targeting spliced XBP1 and unspliced XBP1 in cDNA from P23H-1 retinae at 5 weeks. Rpl19 was used as a normalisation control. (e) Quantification
of RT-PCR using primers targeting spliced XBP1 and unspliced XBP1 in cDNA from P23H-1 rats at P35. The ratio of spliced XBP1 to unspliced XBP1 was normalised to Rpl19
levels and normalised to wild-type XBP1 ratio. Statistical significance was determined by using analysis of variance, *Po0.05, ***Po0.001
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and rod degeneration starts as early as P16.30,36 Similarly, OS
length is decreased by 40% in P40 P23H-1 animals,30 and
retinal sensitivity correlates with OS length in human RP
patients,37 suggesting that changes in the OS might precede
and predict photoreceptor cell loss. P23H rhodopsin cannot
sustain normal OS biogenesis in the absence of wild-type
rhodopsin, and heterozygous P23H knock-in mice have
disrupted disc organisation in their OS.8,9,38 The reasons for
this ultrastructural disruption are not clear at present but might
correspond to insufficient rhodopsin for proper disc formation,
a toxic gain of function of the mutant protein that disrupts the
disc structure or a combination of both these processes. P23H
rhodopsin has a dominant-negative effect on wild-type
rhodopsin,4,6,7 and therefore its presence can lead to lower
levels of both wild-type and mutant rhodopsin through ER
retention and degradation. Furthermore, P23H-GFP expres-
sion in Xenopus rods disrupted discs and destabilised the OS
structure.39 We observed an increase in photoreceptor
survival, OS length, and improved OS organisation in
arimoclomol-treated rats, suggesting that arimoclomol treat-
ment can counteract the dominant effects of P23H rhodopsin.
Importantly, this was not due to an increase in the amount of
soluble rhodopsin, suggesting that the OS disruption seen in
this model is at least partly due to a toxic gain of function of the
P23H protein, which was counteracted by arimoclomol
treatment. These data suggest that preservation of the retinal
structure and photoreceptor survival lead to improved visual
responses in arimoclomol-treated animals.
Arimoclomol enhanced the activation of HSF1 and
expression of Hsp70 in the presence of P23H rod opsin in
both cells and in the retina. This suggests that misfolded
P23H rod opsin can initiate the HSR, in addition to the
published induction of the UPR.15 This activation of the HSR
was potentiated by arimoclomol. Interestingly, the induction
of the HSR through HSF1 activation can protect against
P23H rod opsin aggregation and promote cell viability in cells
and in the retina,19,20 suggesting a potential role in dealing
with misfolded rhodopsin by the HSR. However, the down-
stream targets of the HSR that protect against P23H rod
opsin RP are not known at present. It is possible that there
are specific molecular chaperones that target mutant rod
opsin, or it is possible that it is the co-ordinated action of
several induced chaperones that help reduce aggregation
and/or promote survival.
Interestingly, we observed that arimoclomol treatment not
only potentiated the HSR but also enhanced the UPR;
therefore the upregulation of these dual stress responses
may co-operate to protect photoreceptor cells. There is the
potential for crosstalk between the HSR and the UPR. For
example, in yeast, mild heat shock or constitutively active
Hsf1 can rescue growth defects associated with lack of
functional Ire1, by increasing the levels of BiP.40 The HSR is
also induced by tunicamycin treatment in cells lacking Ire1.40
In addition, heat stress can activate the UPR in mammalian
cells via eIF2a phosphorylation and XBP1 splicing.41 Never-
theless, the data presented here are the first demonstration
that arimoclomol can potentiate the UPR when in the
presence of a misfolded protein in the ER and suggest that
pharmacological manipulation of the HSR and UPR can be
integrated to protect cells from stress.
The HSR and UPR feed downstream to the proteasome
and/or autophagy for destruction of misfolded cytosolic or ER
proteins. ER proteins are destroyed by ERAD, which has been
implicated in P23H rod opsin degradation. EDEM1 recognises
and binds P23H rhodopsin and targets it for ERAD.34 The
clearance of P23H rhodopsin is also regulated by the ERAD
effector protein VCP.42 Interestingly, arimoclomol treatment
resulted in less P23H rod opsin aggregation in cells and the
photoreceptors of transgenic rats without an increase in
overall rhodopsin levels, suggesting an enhancement of
aggregation-prone rod opsin degradation.
All three branches of the UPR are activated by the
dissociation of BiP from their lumenal domains in response to
detection of unfolded or misfolded protein. BiP has also been
implicated in P23H rhodopsin RP. BiP mRNA and protein are
increased in rat models of rhodopsin RP.43,44 Furthermore, BiP
associates with rod opsin in the ER, and overexpression of BiP
improved P23H rod opsin solubility.33 Indeed, overexpression
of BiP via subretinal AAV delivery in P23H-3 rats increased BiP
levels in the retina and preserved retinal function and ONL
thickness.32 BiP levels were increased following arimoclomol
treatment, suggesting that some of the protective effect might
be mediated by increased BiP function.
TheUPR is a protective response to ER stress, but prolonged
activation can promote apoptotic cell death.13 Therefore, the
induction of the UPR, and in particular the PERK branch, has
been implicated in both the protection against misfolded
proteins and also in cell death. For example, in a SODG85R
model of ALS, the expression of mutant GADD34, which lacks
the phosphatase domain, improved disease progression,
probably owing to increased eIF2a phosphorylation repressing
translation.45 Similarly, PERK haploinsufficiency (i.e., mice
heterozygous for a PERK null mutation) decreased survival in
SODG85R mice, as eIF2a phosphorylation was reduced.46
Conversely, increased phosphorylated eIF2a in prion diseased
mice has been linked with increased neuronal cell death, and
overexpression of GADD34 significantly reduced neuron loss.47
Similarly, PERK inhibition in prion mice reduced eIF2a
phosphorylation and slowed disease progression,48 suggesting
that PERK activation and translational blockade by eIF2a
phosphorylation contributes to neuronal cell death. Another
downstream target of PERK is the pro-apoptotic protein CHOP,
which has been implicated in initiating cell death following ER
stress;14 however, ablation of CHOP did not protect photo-
receptors against P23H or T17M mutant rhodopsin.49,50 BiP
expression is upregulated by ATF4 activity after increased
eIF2a phosphorylation,51 hence, in the short term, enhanced
PERK activity may also be protective. We observed increased
eIF2a phosphorylation after arimoclomol treatment, whichmight
contribute to the elevated levels of BiP in combination with IRE1
activation and XBP1 splicing. Furthermore, we did not see an
increase in GADD34 levels after arimoclomol treatment,
suggesting that decreased dephosphorylation may contribute
to increased phosphorylated eIF2a. Therefore, PERK activation
and eIF2a phosphorylation are not necessarily markers that
predict photoreceptor cell death in rhodopsin RP, and our data
suggest that enhancement of the UPR does not lead to
photoreceptor cell death but instead might be protective.
HADs, like arimoclomol, are well documented as heat
shock co-inducers. For example, bimoclomol has been shown
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to upregulate the HSR in models of ischemia,21 and BGP-15
co-induces the HSR in induced-neuropathy models.52 BGP-
15 has also been shown to improve prognosis in a mouse
model of Duchenne muscular dystrophy53 and is currently in
clinical trials for diabetes.54 However, the precise mode of
action of these compounds is still unclear. Bimoclomol has
been shown to increase the activation of HSF1, probably by
prolonging phosphorylation,28 and BGP-15 reduced acetyla-
tion of HSF1, also prolonging its activation.55 HADs can
modify membrane fluidity in response to heat shock, thus
activating downstream signalling targets of the HSR,56 and
research has focussed on the role of HADs at the plasma
membrane, in particular lipid rafts, detergent-resistant mem-
brane regions that have a role in sensing cellular stress.57 The
ability of arimoclomol to potentiate UPR induction by P23H-
GFP also suggests that it is active at the ER membrane.
This study has shown that potentiation of both the HSR and
UPR via arimoclomol treatment can alleviate the damage
caused by the rhodopsin P23H mutation in P23H rats. This
approach might be more effective than stimulating the HSR or
UPR alone. Furthermore, because the effect of arimoclomol is
dependent on the preexisting stress provided by themisfolded
rod opsin, there might be fewer side effects related to the
alteration of the proteostasis machinery other than other
compounds, such as Hsp90 inhibitors.19,20 The ability of
arimoclomol to enhance multiple branches of the cell stress
machinery will also potentially expand the range of diseases
for this drug and other HADs.
Materials and Methods
Reagents and antibodies. Arimoclomol was synthesised by BioBlocks
(Budapest, Hungary). Rod opsin-GFP plasmids were as previously described.4
Lipofectamine and Plus reagent were purchased from Invitrogen (Paisley, UK).
Protease inhibitor cocktail (PIC), phosphatase inhibitor cocktail (PhIC), and 4’,6-
diamidino-2-phenylindole dihydrochloride (DAPI) were from Sigma (Poole, UK).
1D4 mouse monoclonal antibody (mAb) against rod opsin (1.33mg/ml) was a gift
from Professor Robert Molday (University of British Columbia, Vancouver, BC,
Canada) and used at a dilution of 1 : 1500 in all applications. Hsp70 mouse mAb
(1 :1 000) and Hsp90 rat mAb (1 : 1000) were from Stressgen (Ann Arbor, MI, USA).
GFP mouse mAb (1 : 1000) was from Roche (Burgess Hill, UK). HSF1 rat mAb
(1 : 1000) was from Abcam (Cambridge, UK). b-Tubulin mouse mAb (1 : 5000), BiP
rabbit polyclonal antibody (pAb; 1 : 3000), and phosphorylated eIF2a (pSer51) rabbit
pAb (1 : 1000) were from Sigma. ATF4 rabbit pAb (1 : 1000) and ATF6 rabbit pAb
(1 : 1000) were from Santa Cruz (Santa Cruz, CA, USA). Phosphorylated IRE1a
(pSer724) rabbit pAb (1 : 1000) was from Novus Biologicals (Cambridge, UK). Actin
(clone C4) mouse mAb (1 : 5000) was from Millipore (Watford, UK). GADD34 rabbit
pAb (1 : 1000) was from Proteintech (Manchester, UK). Rhodomine-conjugated
peanut agglutinin was from VectorLabs (Peterborough, UK). Goat anti-mouse Alexa
Fluor 488 and goat anti-rabbit Alex Fluor 594 secondary antibodies conjugated IgGs
(1 : 1000) were from Invitrogen. Goat anti-mouse, anti-rat, and anti-rabbit secondary
antibodies conjugated to horseradish peroxidase were from Pierce (Cramlington, UK).
Animals and arimoclomol treatment. Wild-type SD rats were purchased
from Harlan (Blackthorn, UK). P23H-1 and P23H-3 line rats were kindly provided
by Professor Matt LaVail (UCSF, San Francisco, CA, USA). Animals were housed
in 12 : 12 light/dark cycle with food and water available ad libitum. Arimoclomol
was dissolved in water and delivered to animals via intraperitoneal (i.p.) injection.
Animals were treated with arimoclomol at 10mg/kg daily as indicated. All
procedures were conducted according to the UK Home Office regulations under
the Animals (Scientific Procedures) Act 1986, and with local UCL Institute of
Ophthalmology (London, UK) ethics committee approval.
Electroretinography. Scoptopic ERG was performed as previously
described.20,58 Briefly, animals were dark-adapted overnight before being
anaesthetised via ketamine/xylazine i.p. injection. ERG was performed using
platinum loop electrodes on the cornea, and flash stimuli were presented via LED
stimulator. All procedures were carried out under red-light conditions with the
animal on a 37 1C heated pad.
Cell transfection and fluorescence. SK-N-SH cells were cultured and
transfected as previously described.19 Unless indicated, cells were treated with 1mM
arimoclomol for 24 h and added to the cell culture media directly after transfection.
Immunofluorescence fixing and DAPI staining was performed as previously
described.20 LDH activity assay was performed as previously described.19
Immunohistochemistry. For OS measurement studies, eyes from rats were
fixed in 3% v/v glutaraldehyde and 1% w/v paraformaldehyde buffered to pH 7.4 with
0.08M sodium cacodylate-HCl. Fixed eyes were dissected to isolate the anterior
segment and lens. The posterior segments were then rinsed in 0.1M sodium
cacodylate buffer at pH 7.4, osmicated with 1% aqueous osmium tetroxide, and
dehydrated through ascending alcohols (50–90%) and left overnight at room
temperature on a rotator in a 1 : 1 mixture of propylene oxide/absolute alcohol.
Posterior segments were embedded and cured overnight at 60 1C. Semithin and
ultrathin sections were cut using a Leica (Milton Keynes, UK) Ultracut S microtome
fitted with the appropriate type of diamond knife. For light microscopy, semithin
sections were stained with 1% toluidine blue and 1% borax in 50% ethanol. Ultrathin
sections were contrasted for 5min with 1% uranyl acetate in 50% ethanol followed by
Reynold’s lead citrate, before viewing and photographing with a JEOL (Welwyn
Garden City, UK) 1010 TEM operating at 80 kV.
For fluorescence studies, eyes were removed from rats at specified time points
and fixed overnight in 4% paraformaldehyde at 4 1C. Postfixation eyes were
cryoprotected by incubation in 30% sucrose in PBS. Eyes were then frozen and
cyrosectioned as described previously.20 Cryosectioned eyes were incubated in
blocking buffer (3% bovine serum albumin (BSA) and 10% normal goat serum
in PBS) for 1 h at room temperature before incubation with primary antibodies as
indicated. DAPI staining was used to visualise the nuclei.
Imaging and analysis. Cell and retina images were obtained using the
Carl Zeiss (Cambridge, UK) LSM700 laser-scanning confocal microscope. Images
for OS length analysis were taken on a Carl Zeiss LSM510 confocal microscope.
Images were exported from the Zen 2009 (Carl Zeiss) software and prepared
using Adobe (San Jose, CA, USA) Photoshop and Illustrator CS4. Cell
morphology studies were scored as previously described.19 Images for ONL
thickness measurements were taken on a Nikon (Kingston-upon-Thames, UK)
Eclipse 80i. ONL thickness measurements were made on digital images of stained
cryosections, every 500mm from the optic nerve outwards for both the inferior and
superior hemisphere. Results from five animals at each time point were averaged
and represented as a spider plot. All measurements were performed in ImageJ
(http://rsbweb.nih.gov/ij/), and subsequent analysis was performed in Microsoft
Excel (Redmond, WA, USA).
Western blotting and sedimentation assays. Western blotting was
performed as previously described.20 Briefly, SK-N-SH cells were lysed in ice-cold
1% DM buffer with 2% PIC. Frozen rat retinae were lysed in ice-cold RIPA buffer
with 2% PIC and 2% PhIC. The opsin solubility assay in transfected SK-N-SH cells
was performed as previously described.19 The opsin fractionation assay using
transgenic rat retinae was performed as previously described.20 All samples were
separated by SDS-PAGE and analysed by western blotting. Primary antibodies
were diluted in 5% BSA in Tris-buffered saline with 0.05% Tween20 (TBST), and
incubation was carried out overnight at 4 1C using the antibodies listed in Materials
and Methods. After scanning developed films, densitometry analysis was
completed using ImageJ. The average pixel density was measured for each band.
RNA extraction and RT-PCR. Frozen retina were subjected to RNA
extraction using the RNeasy Mini Kit (Qiagen, Crawley, UK), and cDNA synthesis
was performed via reverse transcription (RT) using the SuperScript III First-Strand
Synthesis (Invitrogen) system for RT. Specific amplification of spliced XBP1 was
achieved using the following primers: XBP1sF (from Hirota et al:59 50-GGTC
TGCTGAGTCCGCAGCAGG-30); and XBP1sR (from Samali et al:60 50-GG
GTCCAACTTGTCCAGAATGC-30). Rpl19 was used as an internal reference.15
Primers were: Rpl19F: 50-TACCCTTCCTCTTCCCTATGCC-30; and Rpl19R:
50-TGGACCCCAATGAAACCAAC-30. GoTaq Green (Promega, Southampton,
UK) was used for amplification by PCR with standard cycling conditions.
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Statistical analysis. For the group analysis of western blotting and RT-PCR
quantification, one-way analysis of variance and post-hoc Tukey’s test was used.
For the analysis of all other measurements of paired groups (ERG, ONL thickness,
and OS length measurements), Student’s t-test was used. All statistical analysis
was performed in either the SPSS (version 22, IBM, Armont, NY, USA)
or Microsoft Excel.
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